Apr 29 |
Psychedelic drug developers could benefit from NIH funding for chronic pain
|
Apr 29 |
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
|
Apr 25 |
COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
|
Apr 1 |
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
|
Apr 1 |
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday
|
Mar 31 |
20 Most Depressed Countries in Asia
|
Mar 30 |
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
|
Mar 28 |
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
|
Mar 10 |
10 Alternatives to Antidepressant Medications
|
Mar 7 |
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
|